A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue

Study to investigate the efficacy, safety and tolerability of systemic chemotherapy plus ponsegromab versus systemic chemotherapy plus placebo for the first-line treatment in adult participants with cachexia and metastatic pancreatic ductal adenocardinoma.

Trial Details

NCT ID
NCT06989437
Phase
PHASE2 / PHASE3
Sponsor
Pfizer
Status
RECRUITING
Cancer Type
Pancreatic Cancer
Interventions
  • ponsegromab
  • placebo
Locations (sample)
  • Birmingham, Alabama, United States|33.52066,-86.80249
  • Phoenix, Arizona, United States|33.44838,-112.07404
  • Bryant, Arkansas, United States|34.59593,-92.48905
  • Little Rock, Arkansas, United States|34.74648,-92.28959
  • Encinitas, California, United States|33.03699,-117.29198

Key Eligibility Criteria

  • Signed Informed Consent Document
  • Documented active diagnosis of metastatic pancreatic ductal adenocarcinoma
  • Cachexia defined by Fearon criteria of weight loss
  • Completed 1 x 28-day cycle of first-line systemic nab-paclitaxel and gemcitabine chemotherapy or 2 x 14-day cycles of FOLFIRINOX chemotherapy and p…

For full eligibility, visit ClinicalTrials.gov.

Check If You May Be Eligible

Trialify translates complex eligibility criteria into plain yes-or-no questions to help you understand if this trial might be right for you.

Find Pancreatic Cancer Trials on Trialify →